Recombinant human IL-6 (Cat.NO. HZ-1019) stimulates proliferation of hybridoma (Proteintech mouse anti-GST clone 3G12B10) in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human IL-6 (1 ng/mL HZ-1019) is neutralized by mouse anti-human IL-6 monoclonal antibody 69001-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 10-30 ng/mL.
Recombinant human IL-6 (Cat.NO. HZ-1019) stimulates proliferation of hybridoma (Proteintech mouse anti-GST clone 3G12B10) in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human IL-6 (1 ng/mL HZ-1019) is neutralized by mouse anti-human IL-6 monoclonal antibody 69001-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 3-15 ng/mL. The NeutraControl mouse anti-human IL-6 monoclonal antibody 69501-1-Ig could recognize human IL-6 but could not neutralize human IL-6 activity in the range of 0.06 ng/mL-1000 ng/mL (green curve, refer to top X-right Y axis).
Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 69001-1-Ig (NeutraKine® IL-6 antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).
Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 69001-1-Ig (NeutraKine® IL-6 antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).
Recombinant human TGF beta 1 (Cat.NO. HZ-1011) inhibits IL-4 induced proliferation of mouse HT-2 cells in a dose dependent nammer (blue curve, refer to bottom X-left Y). The activity of human TGF beta 1 (0.5 ng/mL HZ-1011) is neutralized by mouse anti-human TGF beta 1 antibody 69012-1-Ig at serial dose (red curve, refer to top X-right Y). The ND50 is typically 1-5 μg/mL.The NeutraControl mouse anti-human TGF beta 1 monoclonal antibody 69512-1-Ig could recognize human TGF beta 1, but could not neutralize human TGF beta 1 in the range of 0.0061-100 μg/mL(green curve, refer to top X-right Y).
Indirect ELISA was carried out by coating recombinant Human TGF beta 1 (Cat.NO. HZ-1011) at 70 ng/well followed by blocking and adding serial diluted TGF beta 1 antibody 69012-1-Ig and 69512-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.
Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 69012-1-Ig (NeutraKine® TGF beta 1 antibody) at dilution of 1:1000 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).
Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 69012-1-Ig (NeutraKine® TGF beta 1 antibody) at dilution of 1:1000 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).
Recombinant human IL-10 (Cat.NO. HZ-1145) stimulates proliferation of MC/9 cells (mouse mast cell line) in a dose-dependent manner (blue curve, refer to bottom X-left Y). The activity of human IL-10 (10 ng/mL) is neutralized by mouse anti-human IL-10 monoclonal antibody 69018-1-Ig at serial dose (red curve, refer to top X-right Y). The ND50 is typically 50-200 ng/mL.
Recombinant human IL-10 (Cat.NO. HZ-1145) stimulates proliferation of MC/9 cells (mouse mast cell line) in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human IL-10 (10 ng/mL) is neutralized by mouse anti-human IL-10 monoclonal antibody 69018-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 50-200 ng/mL. The NeutraControl mouse anti-human IL-10 monoclonal antibody 69518-1-Ig could recognize human IL-10 but could not neutralize human IL-10 in the range of 7.8125-2000ng/mL(green curve, refer to top X-right Y axis).
Indirect ELISA was carried out by coating recombinant Human IL-10 (Cat.NO. HZ-1145) at 70 ng/well followed by blocking and adding serial diluted IL-10 antibody 69018-1-Ig and 69518-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.
Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 69018-1-Ig (NeutraKine® IL-10 antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).
Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 69018-1-Ig (NeutraKine® IL-10 antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).
Recombinant human IL-17A (Cat.NO. HZ-1113) stimulates HT-1080 cells (human fibroblast cell line) produce IL-6 in a dose dependent manner (blue curve, refer to bottom X-Left Y axis). The activity of human IL-17A (40ng/mL HZ-1113) is neutralized by mouse anti-human IL-17A monoclonal antibody 69021-1-Ig (red curve, refer to top X-right Y axis). The ND50 is typically 200-600ng/mL.
Recombinant human IL-17A (Cat.NO. HZ-1113) stimulates HT-1080 cells (human fibroblast cell line) produce IL-6 in a dose dependent manner (blue curve, refer to bottom X-Left Y axis). The activity of human IL-17A (40ng/mL HZ-1113) is neutralized by mouse anti-human IL-17A monoclonal antibody 69021-1-Ig (red curve, refer to top X-right Y axis). The ND50 is typically 200-600ng/mL. The NeutraControl mouse anti-human IL-17A monoclonal antibody 69521-1-Ig could recognize human IL-17A, but could not neutralize human IL-17A at the range of 0.3051-5 μg/mL(green curve, refer to top X-right Y axis).
Indirect ELISA was carried out by coating recombinant Human IL-17A (Cat.NO. HZ-1113) at 70 ng/well followed by blocking and adding serial diluted IL-17A antibody 69021-1-Ig and 69521-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.
Recombinant IFN beta (Cat.NO. HZ-1298) inhibits TF-1 cell proliferation at dose dependent manner (blue curve, refer to bottom X-left Y). The activity of human IFN beta (10 ng/mL HZ-1298) is neutralized by mouse anti-human IFN beta monoclonal antibody 69013-1-Ig at serial dose (red curve, refer to top X-right Y). The ND50 is typically 5-20 ng/mL.
Recombinant human PDGFbb (Cat.NO. HZ-1308) stimulates proliferation of BALB/3T3 (mouse fibroblast cell line) in a dose dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human PDGFbb (20ng/mL HZ-1308) is neutralized by mouse anti-human PDGFbb monoclonal antibody 69020-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 20-50 μg/mL.
Recombinant human PDGF bb (Cat.NO. HZ-1308) stimulates the proliferation of BALB/3T3 cells (mouse fibroblast cell) in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human PDGF bb (20 ng/mL HZ-1308) is neutralized by mouse anti-human PDGF bb monoclonal antibody 69020-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 20-50 μg/mL. The NeutraControl mouse anti-human PDGF bb monoclonal antibody 69520-1-Ig could recognize human PDGF bb, but could not neutralize human PDGF bb at the range of 3.125-200 μg/mL(green curve, refer to top X-right Y axis).
Indirect ELISA was carried out by coating recombinant Human PDGF bb (Cat.NO. HZ-1308) at 70 ng/well followed by blocking and adding serial diluted PDGF bb antibody 69020-1-Ig and 69520-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.
Recombinant human TNF alpha (Cat.NO. HZ-1014) inhibits the growth of L-929 cell line in the presence of actinomycin D in a dose dependent manner (blue curve, refer to bottom X-left Y). The activity elicited by recombinant human TNF alpha (0.05 ng/mL HZ-1014) is neutralized by mouse anti-human TNF alpha monoclonal antibody 69002-1-Ig at serial dose (red curve, refer to top X-right Y). The ND50 is typically 10-50 ng/mL. The NeutraControl mouse anti-human TNF alpha monoclonal antibody 69502-1-Ig, generated from the same immunogen, could recognize human TNF alpha, but could not neutralize human TNF alpha at the range of 0.128-10000ng/mL (green curve, refer to top X-right Y).
Indirect ELISA was carried out by coating recombinant Human TNF Alpha (Cat.NO. HZ-1014) at 70 ng/well followed by blocking and adding serial diluted TNF Alpha antibody 69002-1-Ig and 69502-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.
Recombinant human IL-10 (Cat.NO. HZ-1145) stimulates proliferation of MC/9 cells (mouse mast cell line) in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human IL-10 (10 ng/mL) is neutralized by mouse anti-human IL-10 monoclonal antibody 69018-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 50-200 ng/mL. The NeutraControl mouse anti-human IL-10 monoclonal antibody 69518-1-Ig could recognize human IL-10 but could not neutralize human IL-10 in the range of 7.8125-2000ng/mL(green curve, refer to top X-right Y axis).
Indirect ELISA was carried out by coating recombinant Human IL-10 (Cat.NO. HZ-1145) at 70 ng/well followed by blocking and adding serial diluted IL-10 antibody 69018-1-Ig and 69518-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.
Recombinant human IL-6 (Cat.NO. HZ-1019) stimulates proliferation of hybridoma (Proteintech mouse anti-GST clone 3G12B10) in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human IL-6 (1 ng/mL HZ-1019) is neutralized by mouse anti-human IL-6 monoclonal antibody 69001-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 10-30 ng/mL. The NeutraControl mouse anti-human IL-6 monoclonal antibody 69501-1-Ig could recognize human IL-6 but could not neutralize human IL-6 activity in the range of 0.06 ng/mL-1000 ng/mL (green curve, refer to top X-right Y axis).
Indirect ELISA was carried out by coating recombinant Human IL-6 (Cat.NO. HZ-1019) at 70 ng/well followed by blocking and adding serial diluted IL-6 antibody 69001-1-Ig and 69501-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.
Recombinant human PDGF bb (Cat.NO. HZ-1308) stimulates the proliferation of BALB/3T3 cells (mouse fibroblast cell) in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human PDGF bb (20 ng/mL HZ-1308) is neutralized by mouse anti-human PDGF bb monoclonal antibody 69020-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 20-50 μg/mL. The NeutraControl mouse anti-human PDGF bb monoclonal antibody 69520-1-Ig could recognize human PDGF bb, but could not neutralize human PDGF bb at the range of 3.125-200 μg/mL(green curve, refer to top X-right Y axis).
Indirect ELISA was carried out by coating recombinant Human PDGF bb (Cat.NO. HZ-1308) at 70 ng/well followed by blocking and adding serial diluted PDGF bb antibody 69020-1-Ig and 69520-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.
Recombinant human IFN-gamma (Cat.NO. HZ-1301) inhibits HT-29 cell line (human colorectal adenocarcinoma cell line) proliferation in the prescence of 0.5 ng/mL TNF alpha in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human IFN-gamma (2ng/mL HZ-1301 axis) is neutralized by mouse anti-human IFN-gamma monoclonal antibody 69007-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 100-500 ng/mL.
Recombinant human IFN-gamma (Cat.NO. HZ-1301) inhibits HT-29 cell line (human colorectal adenocarcinoma cell line) proliferation in the prescence of 0.5 ng/mL TNF alpha in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human IFN-gamma (5 ng/mL HZ-1301 axis) is neutralized by mouse anti-human IFN-gamma monoclonal antibody 69007-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 100-500 ng/mL.
The NeutraControl mouse anti-human IFN-gamma monoclonal antibody 69507-1-Ig could recognize human IFN-gamma but could not neutralize human IFN-gamma in the range of 0.00244-40 μg/mL (green curve, refer to top X-right Y axis).
Indirect ELISA was carried out by coating recombinant Human IFN gamma (Cat.NO. HZ-1301) at 70 ng/well followed by blocking and adding serial diluted IFN gamma antibody 69007-1-Ig and 69507-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.
Recombinant human FGF Basic (Cat.NO. HZ-1285) stimulates the proliferation of BALB/3T3 cells (mouse fibroblast cell) at low FBS condition in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human FGF Basic (0.1 ng/mL HZ-1285) is neutralized by mouse anti-human FGF Basic monoclonal antibody 69024-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 1-10 μg/mL. Mouse IgG1 Isotype Control monoclonal antibody 66360-1-Ig was served as control (green curve, refer to top X-right Y axis).
Recombinant human VEGF165 (Cat.NO. HZ-1038) stimulates proliferation of HUVEC (human umbilical vein endothelial) cell line in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human VEGF165 (10 ng/mL HZ-1038) is neutralized by mouse anti-human VEGF165/121 monoclonal antibody 69025-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 0.5-2 μg/mL. The NeutraControl mouse anti-human VEGF165 antibody 69525-1-Ig could recognize human VEGF165 but could not neutralize human VEGF165 acitivity in the range of 0.00244-40 μg/mL (green curve, refer to top X-right Y axis).
Indirect ELISA was carried out by coating recombinant Human VEGF165 (Cat.NO. HZ-1038) and VEGF121 (Cat.NO. HZ-1204) respectively at 70 ng/well followed by blocking and adding serial diluted VEGF165/121 antibody 69025-1-Ig and VEGF165 antibody 69525-1-Ig respectively. HRP-goat anti-mouse was used for detection. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm. The result suggsts that 69025-1-Ig recognizes both VEGF165 and VEGF121 while 69525-1-Ig recognize VEGF165 only.
Recombinant human EPO (Cat.NO. HZ-1168) stimulates TF-1 cells (human erythroleukemic cell line) in a dose-dependent nammer (blue curve, refer to bottom X-left Y). The activity of human EPO (1 ng/mL HZ-1168) was neutralized by mouse anti-human EPO monoclonal antibody 69019-1-Ig at serial dose (red curve, refer to top X-right Y). The ND50 is typically 2-5 μg/mL. The NeutraControl mouse anti-human EPO monoclonal antibody 69519-1-Ig could recognize human EPO, but could not neutralize human EPO in the range of 0.019-80 μg/mL(green curve, refer to top X-right Y).
Indirect ELISA was carried out by coating recombinant Human EPO (Cat.NO. HZ-1168) at 70 ng/well followed by blocking and adding serial diluted EPO antibody 69019-1-Ig and 69519-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.
Recombinant human FLT3 Ligand (Cat.NO. HZ-1151) stimulates proliferation of OCI-AML5 cells in a dose-dependent manner (blue curve, refer to bottom X-left Y). The activity of human FLT3 (1 ng/mL) is neutralized by mouse anti-human FLT3 Ligand monoclonal antibody 69032-1-Ig at serial dose (red curve, refer to top X-right Y). The ND50 is typically 0.01-0.05 μg/mL.The control mouse anti-human FLT3 Ligand monoclonal antibody 69532-1-Ig could recognize human FLT3 Ligand, but could not neutralize human FLT3 Ligand at serial does at the range of 0.12207-2000ng/mL(green curve, refer to top X-right Y).
Indirect ELISA was carried out by coating recombinant Human FLT3 Ligand (Cat.NO. HZ-1151) at 70 ng/well followed by blocking and adding serial diluted FLT3 Ligand antibody 69032-1-Ig and 69532-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.
Recombinant human HGF (Cat.NO. HZ-1084) stimulates Saos-2 cells (human osteosarcoma cell) produce IL-11 in a dose dependent manner (blue curve, refer to bottom X-Left Y axis). The activity of human HGF (50ng/mL HZ-1084) is neutralized by mouse anti-human HGF monoclonal antibody 69027-1-Ig (red curve, refer to top X-right Y axis). The ND50 is typically 2-8μg/mL.The NeutraControl mouse anti-human HGF antibody 69527-1-Ig could recognize human HGF but could not neutralize human HGF acitivity in the range of 0.3125-40 μg/mL (green curve, refer to top X-right Y axis).
Indirect ELISA was carried out by coating recombinant Human HGF (Cat.NO. HZ-1084) at 70 ng/well followed by blocking and adding serial diluted Thrombopoietin antibody 69027-1-Ig and 69527-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.
Recombinant human IFN-gamma (Cat.NO. HZ-1301) inhibits HT-29 cell line (human colorectal adenocarcinoma cell line) proliferation in the prescence of 0.5 ng/mL TNF alpha in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human IFN-gamma (5 ng/mL HZ-1301 axis) is neutralized by mouse anti-human IFN-gamma monoclonal antibody 69007-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 100-500 ng/mL. The NeutraControl mouse anti-human IFN-gamma monoclonal antibody 69507-1-Ig could recognize human IFN-gamma but could not neutralize human IFN-gamma in the range of 0.00244-40 μg/mL (green curve, refer to top X-right Y axis).
Indirect ELISA was carried out by coating recombinant Human IFN gamma (Cat.NO. HZ-1301) at 70 ng/well followed by blocking and adding serial diluted IFN gamma antibody 69007-1-Ig and 69507-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.
Recombinant human IL-12 (Cat.NO. HZ-1256) stimulates NK-92 cells produce IFN gamma in a dose dependent manner (blue curve, refer to bottom X-Left Y axis). The activity of human IL-12 (10 ng/mL HZ-1256) is neutralized by mouse anti-human IL-12 p35 monoclonal antibody 69029-1-Ig (red curve, refer to top X-right Y axis). The ND50 is typically 0.5-1 μg/mL. The control mouse anti-human IL-12 p35 monoclonal antibody 69529-1-Ig could recognize human IL-12, but could not neutralize human IL-12 at serial does at the range of 0.00122-20 μg/mL(green curve, refer to top X-right Y).
Indirect ELISA was carried out by coating recombinant Human IL-12 (Cat.NO. HZ-1256) and IL-12 p40 (Cat.NO. HZ-1321) respectively at 70 ng/well followed by blocking and adding serial diluted 69029-1-Ig , 69529-1-Ig and 69006-1-Ig respectively. HRP-goat anti-mouse was used for detection. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm. The result suggests that 69029-1-Ig and 69529-1-Ig only recognize IL-12(p35 and p40 heterodimer) but not recognize IL-12 p40.
Recombinant human IL-17A (Cat.NO. HZ-1113) stimulates HT-1080 cells (human fibroblast cell line) produce IL-6 in a dose dependent manner (blue curve, refer to bottom X-Left Y axis). The activity of human IL-17A (40ng/mL HZ-1113) is neutralized by mouse anti-human IL-17A monoclonal antibody 69021-1-Ig (red curve, refer to top X-right Y axis). The ND50 is typically 200-600ng/mL. The NeutraControl mouse anti-human IL-17A monoclonal antibody 69521-1-Ig could recognize human IL-17A, but could not neutralize human IL-17A at the range of 0.3051-5 μg/mL(green curve, refer to top X-right Y axis).
Indirect ELISA was carried out by coating recombinant Human IL-17A (Cat.NO. HZ-1113) at 70 ng/well followed by blocking and adding serial diluted IL-17A antibody 69021-1-Ig and 69521-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.
Recombinant human IL-23 (Cat.NO. HZ-1254) induces in vitro cultured mouse splenocytes to secret IL-17A in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human IL-23 (4 ng/mL HZ-1254) is neutralized by mouse anti-human IL-23 p19 monoclonal antibody 69006-1-Ig at serial dose (red curve, refer to top X-right Y). The ND50 is typically 8-30 ng/mL. The NeutraControl mouse anti-human IL-23 p19 monoclonal antibody 69506-1-Ig could recognize human IL-23, but could not neutralize human IL-23 in the range of 0.244-4000ng/mL(green curve, refer to top X-right Y axis).
Indirect ELISA was carried out by coating recombinant Human IL-23 (Cat.NO. HZ-1254) at 70 ng/well followed by blocking and adding serial diluted IL-23 antibody 69006-1-Ig and 69506-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.
Recombinant human M-CSF(Cat.NO. HZ-1192) stimulates proliferation of OCI-AML5 cells in a dose-dependent manner (blue curve, refer to bottom X-left Y). The activity of human M-CSF (5 ng/mL) is neutralized by mouse anti-human M-CSF monoclonal antibody 69033-1-Ig at serial dose (red curve, refer to top X-right Y). The ND50 is typically 0.1-0.4 μg/mL. The control mouse anti-human M-CSF monoclonal antibody 69533-1-Ig could recognize human M-CSF, but could not neutralize human M-CSF at serial does at the range of 0.976563-16000ng/mL(green curve, refer to top X-right Y).
Indirect ELISA was carried out by coating recombinant Human M-CSF (Cat.NO. HZ-1192) at 70 ng/well followed by blocking and adding serial diluted M-CSF antibody 69033-1-Ig and 69533-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.